Literature DB >> 34651117

Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.

Hannah Rinehardt1, Mahmoud Kassem2,3, Evan Morgan2,3, Marilly Palettas4, Julie A Stephens4, Anupama Suresh2,3, Akansha Ganju2,3, Maryam Lustberg2,3, Robert Wesolowski2,3, Sagar Sardesai2,3, Daniel Stover2,3, Jeffrey Vandeusen2,3, Mathew Cherian2,3, Maria Del Pilar Guillermo Prieto Eibl5, Abdul Miah2, Iyad Alnahhas5, Pierre Giglio5, Vinay K Puduvalli5, Bhuvaneswari Ramaswamy2,3, Nicole Williams2,3, Anne M Noonan2.   

Abstract

OBJECTIVE: Leptomeningeal carcinomatosis (LMC), a common complication of advanced malignancies, is associated with high morbidity and mortality, yet diagnosis and treatment decisions remain challenging. This study describes the diagnostic and treatment modalities for LMC and identifies factors associated with overall survival (OS).
MATERIALS AND METHODS: We performed a single-institution retrospective study (registration #: OSU2016C0053) of 153 patients diagnosed with LMC treated at The Ohio State University, Comprehensive Cancer Center, (OSUCCC)-James between January 1, 2010 and December 31, 2015.
RESULTS: Median age at diagnosis was 55.7 years, and 61% had Eastern Cooperative Oncology Group baseline performance status ≤1. Most common primary tumors were breast (43%), lung (26%), and cutaneous melanoma (10%). At presentation, most patients were stage III-IV (71%) with higher grade tumors (grade III: 46%). Metastases to bone (36%), brain (33%), and lung (12%) were the most common sites with a median of 0.5 years (range, 0-14.9 years) between the diagnosis of first metastasis and of LMC. 153 (100%) patients had MRI evidence of LMC. Of the 67 (44%) who underwent lumbar puncture (LP), 33 (22%) had positive cerebrospinal fluid (CSF) cytology. Most patients received radiotherapy for LMC (60%) and chemotherapy (93%) for either the primary disease or LMC. 28 patients received intrathecal chemotherapy, 22 of whom had a primary diagnosis of breast cancer. 98% died with median OS of all patients was 1.9 months (95% CI: 1.3-2.5 months).
CONCLUSION: Despite improved treatments and targeted therapies, outcomes of LMC remain extremely poor. Positive CSF cytology was associated with lower OS in patients who had cytology assessed and specifically in patients with breast cancer. CSF cytology serves as an important indicator for prognosis and helps aid in developing individualized therapeutic strategies for patients with LMC. ©Copyright 2021 by Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  Leptomeningeal carcinomatosis; breast cancer; cerebrospinal fluid; magnetic resonance imaging; metastasis

Year:  2021        PMID: 34651117      PMCID: PMC8496125          DOI: 10.4274/ejbh.galenos.2021.2021-4-10

Source DB:  PubMed          Journal:  Eur J Breast Health


  33 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Leptomeningeal metastases in the MRI era.

Authors:  J L Clarke; H R Perez; L M Jacks; K S Panageas; L M Deangelis
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

3.  The central nervous system in childhood leukemia. I. The arachnoid.

Authors:  R A Price; W W Johnson
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

4.  Leptomeningeal metastasis.

Authors:  Marc C Chamberlain
Journal:  Semin Neurol       Date:  2010-06-24       Impact factor: 3.420

5.  Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

Authors:  M H Geukes Foppen; D Brandsma; C U Blank; J V van Thienen; J B Haanen; W Boogerd
Journal:  Ann Oncol       Date:  2016-03-08       Impact factor: 32.976

6.  Meningeal carcinomatosis in breast cancer.

Authors:  H Y Yap; B S Yap; C K Tashima; A DiStefano; G R Blumenschein
Journal:  Cancer       Date:  1978-07       Impact factor: 6.860

7.  Leptomeningeal metastases: 111indium-DTPA CSF flow studies.

Authors:  M C Chamberlain; J Corey-Bloom
Journal:  Neurology       Date:  1991-11       Impact factor: 9.910

8.  Leptomeningeal metastases: reduction in regional cerebral blood flow and cognitive impairment.

Authors:  T Siegal; B Mildworf; D Stein; E Melamed
Journal:  Ann Neurol       Date:  1985-01       Impact factor: 10.422

9.  Diffuse involvement of the leptomeninges by tumour--a clinical and pathological study of 63 cases.

Authors:  R Boyle; M Thomas; J H Adams
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

10.  Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine.

Authors:  Jan-Paul Bohn; Vera Reinstadler; Georg Pall; Günther Stockhammer; Michael Steurer; Herbert Oberacher; Dominik Wolf
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

View more
  1 in total

1.  Ophthalmoplegia in a Her2+ and β-hCG+ Patient With Leptomeningeal Carcinomatosis Secondary to Gastric Adenocarcinoma.

Authors:  Zachary Falk; Mei Bou Nasif; Nabil Fallouh
Journal:  Cureus       Date:  2022-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.